Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction.
Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald E. Gibson CM, et al. Among authors: van de werf f. J Am Coll Cardiol. 1999 Nov 1;34(5):1403-12. doi: 10.1016/s0735-1097(99)00397-6. J Am Coll Cardiol. 1999. PMID: 10551685
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
Gibson CM, Cannon CP, Murphy SA, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Berioli S, Weaver WD, Van de Werf F, Braunwald E. Gibson CM, et al. Among authors: van de werf f. Am J Cardiol. 1999 Nov 1;84(9):976-80. doi: 10.1016/s0002-9149(99)00483-x. Am J Cardiol. 1999. PMID: 10569649 Clinical Trial.
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E. Cannon CP, et al. Among authors: van de werf f. Circulation. 1998 Dec 22-29;98(25):2805-14. doi: 10.1161/01.cir.98.25.2805. Circulation. 1998. PMID: 9860780 Clinical Trial.
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.
Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Antman EM, et al. Among authors: van der wieken r, van de werf f. Circulation. 1999 Jun 1;99(21):2720-32. doi: 10.1161/01.cir.99.21.2720. Circulation. 1999. PMID: 10351964 Clinical Trial.
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.
de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey MJ, Van Der Wieken R, Van De Werf F, Braunwald E. de Lemos JA, et al. Among authors: van der wieken r, van de werf f. Circulation. 2000 Jan 25;101(3):239-43. doi: 10.1161/01.cir.101.3.239. Circulation. 2000. PMID: 10645918 Clinical Trial.
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AA, Gibson CM, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS. Coulter SA, et al. Among authors: van de werf f. Circulation. 2000 Jun 13;101(23):2690-5. doi: 10.1161/01.cir.101.23.2690. Circulation. 2000. PMID: 10851205 Clinical Trial.
757 results